101 related articles for article (PubMed ID: 9191520)
21. Anal carcinoma: surgery does not influence prognosis when performed prior to concurrent radiochemotherapy.
Badakhshi H; Budach V; Wust P; Graf R
Anticancer Res; 2013 Sep; 33(9):4111-5. PubMed ID: 24023357
[TBL] [Abstract][Full Text] [Related]
22. Anal canal carcinoma: early-stage tumors < or =10 mm (T1 or Tis): therapeutic options and original pattern of local failure after radiotherapy.
Ortholan C; Ramaioli A; Peiffert D; Lusinchi A; Romestaing P; Chauveinc L; Touboul E; Peignaux K; Bruna A; de La Roche G; Lagrange JL; Alzieu C; Gerard JP
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):479-85. PubMed ID: 15890590
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of apoptosis-regulating protein expression in anal squamous cell carcinoma.
Allal AS; Waelchli L; Bründler MA
Clin Cancer Res; 2003 Dec; 9(17):6489-96. PubMed ID: 14695153
[TBL] [Abstract][Full Text] [Related]
24. Node-negative T1-T2 anal cancer: radiotherapy alone or concomitant chemoradiotherapy?
Zilli T; Schick U; Ozsahin M; Gervaz P; Roth AD; Allal AS
Radiother Oncol; 2012 Jan; 102(1):62-7. PubMed ID: 21993403
[TBL] [Abstract][Full Text] [Related]
25. Conservative versus nonconservative treatment of epidermoid carcinoma of the anal canal for tumors longer than or equal to 5 centimeters. A retrospective comparison.
Touboul E; Schlienger M; Buffat L; Ozsahin M; Belkacemi Y; Pene F; Balosso J; Lefkopoulos D; Parc R; Tiret E
Cancer; 1995 Feb; 75(3):786-93. PubMed ID: 7828129
[TBL] [Abstract][Full Text] [Related]
26. Clinical radiobiology of stage T2-T3 bladder cancer.
Majewski W; Maciejewski B; Majewski S; Suwinski R; Miszczyk L; Tarnawski R
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):60-70. PubMed ID: 15337540
[TBL] [Abstract][Full Text] [Related]
27. Time-dose considerations in the treatment of anal cancer.
Constantinou EC; Daly W; Fung CY; Willett CG; Kaufman DS; DeLaney TF
Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):651-7. PubMed ID: 9336145
[TBL] [Abstract][Full Text] [Related]
28. Anal canal cancer treatment: practical limitations of routine prescription of concurrent chemotherapy and radiotherapy.
Chauveinc L; Buthaud X; Falcou MC; Mosseri V; De la Rochefordière A; Pierga JY; Girodet J; Salmon RJ
Br J Cancer; 2003 Dec; 89(11):2057-61. PubMed ID: 14647138
[TBL] [Abstract][Full Text] [Related]
29. Impact of overall treatment time on local control of anal cancer treated with radiochemotherapy.
Graf R; Wust P; Hildebrandt B; Gögler H; Ullrich R; Herrmann R; Riess H; Felix R
Oncology; 2003; 65(1):14-22. PubMed ID: 12837978
[TBL] [Abstract][Full Text] [Related]
30. Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series.
Franco P; Mistrangelo M; Arcadipane F; Munoz F; Sciacero P; Spadi R; Migliaccio F; Angelini V; Bombaci S; Rondi N; Numico G; Ragona R; Cassoni P; Morino M; Racca P; Ricardi U
Cancer Invest; 2015 Jul; 33(6):259-66. PubMed ID: 25950188
[TBL] [Abstract][Full Text] [Related]
31. Definitive radiotherapy for squamous cell carcinoma of the anal canal.
Rabbani AN; Zlotecki RA; Kirwan J; George TJ; Morris CG; Rout WR; Mendenhall WM
Am J Clin Oncol; 2010 Feb; 33(1):47-51. PubMed ID: 19704368
[TBL] [Abstract][Full Text] [Related]
32. [The therapeutic results and early and late toxicities of the treatment of anal canal carcinoma by radiotherapy or chemoradiotherapy].
Sommer K; Brockmann WP; Wiegel T; Krüll A; Hübener KH; Birk S
Strahlenther Onkol; 1991 Aug; 167(8):445-51. PubMed ID: 1909466
[TBL] [Abstract][Full Text] [Related]
33. Patterns of recurrence in squamous cell carcinoma of the anal canal.
Luna-Pérez P; Fernández A; Labastida S; Lira-Puerto V; Vázquez-Curiel JA; Herrera L
Arch Med Res; 1995; 26(3):213-9. PubMed ID: 8580670
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of helical tomotherapy with daily image guidance in anal canal cancer patients.
De Bari B; Jumeau R; Bouchaab H; Vallet V; Matzinger O; Troussier I; Mirimanoff RO; Wagner AD; Hanhloser D; Bourhis J; Ozsahin EM
Acta Oncol; 2016 Jun; 55(6):767-73. PubMed ID: 27034083
[TBL] [Abstract][Full Text] [Related]
35. Role of brachytherapy in the boost management of anal carcinoma with node involvement (CORS-03 study).
Moureau-Zabotto L; Ortholan C; Hannoun-Levi JM; Teissier E; Cowen D; Salem N; Lemanski C; Ellis S; Resbeut M
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):e135-42. PubMed ID: 23195780
[TBL] [Abstract][Full Text] [Related]
36. [The prognostic factors following the simultaneous radiochemotherapy of anal canal carcinoma in a multicenter series of 139 patients].
Grabenbauer GG; Panzer M; Hültenschmidt B; Döker R; Huber K; Kuhne-Velte HJ; Hutter M; Rühl U; Budach V; Wendt T
Strahlenther Onkol; 1994 Jul; 170(7):391-9. PubMed ID: 8052938
[TBL] [Abstract][Full Text] [Related]
37. Elective inguinal node irradiation in early-stage T2N0 anal cancer: prognostic impact on locoregional control.
Zilli T; Betz M; Bieri S; Ris F; Roche B; Roth AD; Allal AS
Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):60-6. PubMed ID: 23608237
[TBL] [Abstract][Full Text] [Related]
38. [The anal canal: 2 cycles of radiochemotherapy and boost brachytherapy].
Valentini V; Mantello G; Luzi S; Genovesi D; Smaniotto D; Mantini G; Coco C; Ratto C; Sofo L; Cellini N
Radiol Med; 1997 Apr; 93(4):451-6. PubMed ID: 9244925
[TBL] [Abstract][Full Text] [Related]
39. Role of dose intensity in conservative treatment of anal canal carcinoma. Report of 35 cases.
Ceresoli GL; Ferreri AJ; Cordio S; Villa E
Oncology; 1998; 55(6):525-32. PubMed ID: 9778618
[TBL] [Abstract][Full Text] [Related]
40. Combined chemotherapy--radiotherapy of anal cancer.
Zucali R; Doci R; Bombelli L
Int J Radiat Oncol Biol Phys; 1990 Nov; 19(5):1221-3. PubMed ID: 2254116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
